Abstract. Hypoxia is an essential feature of the microenvironment of solid tumors, which regulates a variety of transcription factors including hypoxia-inducible factor-1α (HIF-1α). HIF-1α overexpression enhances tumor angiogenesis via upregulation of vascular endothelial growth factor (VEGF) and some other hypoxia-inducible angiogenic factors, which lead to a more aggressive tumor phenotype, tumor metastasis and resistance to radiation and chemotherapy. In this study, we found that a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), inhibited cell proliferation and invasion, blocked the cell cycle, and induced cell apoptosis in a dose-and time-dependent manner in the human tongue squamous cell carcinoma (TSCC) SCC-6 cell line in vitro. Furthermore, TSA reduced both basal levels and hypoxia-induced HIF-1α protein accumulation but not HIF-1α mRNA levels, and both protein and mRNA levels of VEGF expression. These results showed that TSA had a potent anticancer activity on TSCC cells, suggesting that TSA could be a promising drug targeting tumor angiogenesis via inhibition of HIF-1α and VEGF expression in the development of an effective chemopreventive and anticancer agent on human TSCCs.
Introduction
Oxygen is essential for the cells and tissues in maintaining their function and integrity. Lack of oxygen often occurs in the central area of solid tumors as well as in embryonic development (1) (2) (3) , which leads to a more aggressive tumor phenotypes, characterized by abnormal angiogenesis, invasion, metastasis and resistance to radiation and chemotherapy (4, 5) . Angiogenesis not only has strong implications in homeostasis, but also plays an integral role in solid tumor survival, progression and metastasis (6) . Hypoxia regulates a number of different transcription factors that may be vital in hypoxia-induced cell responses including hypoxia-inducible factor (HIF-1), which regulates hypoxia-inducible angiogenic factors such as vascular endothelial growth factor(VEGF) and the glycolytic enzymesery (1, 7) . VEGF is a survival factor in endothelial and tumor cells via VEGF receptors which are upregulated by hypoxia (8) (9) (10) (11) . This stimulates the cell to adapt to hypoxic microenvironment. Thus, enhancement of angiogenesis by hypoxia is a prerequisite for progressive growth and metastasis of solid tumors (12) .
Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription factor consisting of two subunits: HIF-1α and HIF-1β. HIF-1α is ubiquitously found in human tissues undergoing rapid ubiquitination and proteasomal degradation under normoxic conditions and stabilizes under hypoxic conditions. The expression of HIF-1α is strictly regulated by low oxygen tension. HIF-1α is also responsible for cell adaptation to both normoxic and hypoxic conditions. The mRNA and protein levels of HIF-1β, also called aryl hydrocarbon receptor nuclear translocator (ARNT) (13) express constantly and are not connected with oxygen tension (14) . Under normoxic conditions, the oxygen-dependent degradation domain (ODDD) of HIF-1α interacts with the von Hippel-Lindau protein (pVHL) ubiquitin E3 ligase complex. Such HIF-1α/von Hippel-Lindau protein interaction requires oxygen and iron-dependent hydroxylation of proline residues (Pro402 and Pro564) in HIF-1α protein and inhibits the binding of transcriptional co-activators p300 and CBP of HIF-1α protein via the 26S proteasome (15) (16) (17) (18) (19) (20) .
Under hypoxic conditions, HIF-1α protein accumulates and stabilizes by remaining unhydroxylated, and translocates into the nucleus where it dimerizes with HIF-1β and forms an active complex (21) . The formed complex initiates transcriptional activation of its target genes via binding to hypoxia response element (HRE) located in the promoter and enhancer regions (14, 22) . These target genes include erythropoiesis, glycolysis (short-term solution) and angiogenesis (long-term solution) (23) which are essential for adaptation and survival under hypoxic conditions. Previous clinical research reported that over expression of HIF-1α has been observed in many human tumors including breast, prostate, brain, lung, tongue and their metastases, and is closely related to tumor angiogenesis, progression and invasion, and resistance to radiation and chemotherapy.
Histone acetyltransferases (HAT) and histone deacetylases (HDAC), which has been considered as transcriptional coactivator and corepressor, play vital roles in regulation of gene transcription in many cell types (24) . HDAC controls gene expression, transport ubiquitinated protein aggregates, and deacetylate proteins (25) (26) (27) . Inhibition of HDAC activity generally blocks the cell cycle and may affect cell proliferation and apoptosis (28, 29) which is closely connected with tumorigenesis and tumor progression. Some specific HDAC inhibitors have been used to elucidate HDAC function and are suggested as a therapy for some types of cancer (30) which makes HDAC a promising target of anti-cancer activity. We investigated a specific HDAC inhibitor, trichostatin A (TSA), which was reported to be able to block cell cycle at G 1 and G 2 /M phase, to inhibit cell proliferation and apoptosis in several tumor cell lines and greatly suppress tumor angiogenesis both in vitro and in vivo (12) , had the same effect on human TSCC SCC-6 cells in dose-and time-dependent manner. Furthermore, we demonstrated that TSA inhibited both basal level and hypoxiainduced HIF-1α protein accumulation and VEGF expression in vitro, providing further evidence that TSA could be a potential anticancer agent on human TSCC by targeting the well-known tumor survival factor HIF-1α and its downstream gene VEGF, under hypoxia.
Materials and methods

Reagents and antibodies.
Trichostatin A (TSA) was purchased from Sigma (St. Louis, MO, USA) and dissolved at a concentration of 3 mmol/l in dehydrated alcohol as a stock solution, stored at -20˚C. Deferoxamine mesylate (DFX) was purchased from Sigma and dissolved in normal saline water at 50 mg/ml as a stock solution, stored at -20˚C. Antibodies for HIF-1α and VEGF were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), stored at 4˚C.
Cell line and cell culture. Human tongue squamous cell carcinoma SCC-6 cell lines were provided by Dr Huang Xin, Beijing Stomatological Hospital, Capital Medical University, Beijing, China. SCC-6 cells were cultured in Dulbecco's modified Eagle's medium/F12 (DMEM/F12=1:1) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 g/ml streptomycin. The cultures were incubated at 37˚C in a humidified atmosphere with 5% CO 2 . To simulate hypoxic conditions, cells were treated with the hypoxia mimetic compound DFX (150 µmol/l) instead of cultured at 5% CO 2 with 1% O 2 balanced with N 2 (31, 32) .
Cell proliferation assay. SCC-6 cells were plated in 96-well plates (1x10 4 /well) and treated with different concentrations of TSA (0, 200, 400, 800, 1600, 3200 nmol/l) at indicated time intervals (0, 12, 24, 48 h), and equivalent dehydrated alcohol for control groups. Then cell proliferation was analyzed by MTT colorimetric assay which determines viable cells by detecting conversion of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide to a purple formazan product (33) . The cells were incubated with MTT solution (1 mg/ml in DMEM/F12) for 4 h at 37˚C and carefully observed to exclude crystal formation outside the cells. Then the medium was decanted, and dimethyl sulphoxide (DMSO, 150 µl/well) added to dissolve the formazan crystals. The number of viable cells correlated with the absorbance (optical density, OD) was measured at 490 nm by Synergy 2 (BioTek). Cell viability equals the difference of OD experiment minus OD blank divided by the difference of OD control minus OD blank . Each experiment was performed in triplicate and repeated three times.
Cell apoptosis. SCC-6 cells were treated with TSA at the above concentrations for 6, 12, 24 h. After harvested, the cells were washed twice with PBS and resuspended in binding buffer. Then incubated for 15 min with 5 µl of Annexin V-FlITC antibody and 10 µl of propidium iodine (50 mg/ml) at room temperature in the dark according to the manufacturer's protocol prior to FACS analysis. Both early and late stages of apoptotic SCC-6 cells induced by TSA were detected by a flow cytometer. The presence of apoptotic cells was scored by monitoring the loss of cell membrane phospholipid asymmetry, resulting in the externalization of phosphatidylserine to the outer membrane without loss of membrane integrity (34) .
Cell cycle analysis. SCC-6 cells were plated in 6-well plates (1x10 6 /well) after reaching 80% confluence, 12 h later cells were treated with different concentrations of TSA (0, 50, 100, 200, 400, 800 nmol/l), then incubated for 24 h. Cells were washed in ice-cold PBS and harvested by trypsinization. Centrifuged at 1000 rpm for 5 min, the supernatant was discarded, propidium iodine (10 µg/ml) was added supplemented with RNaseA (200 µg/ml) to the cells for 30 min at 37˚C in the dark, then analysed by a flow cytometer of FACSCanto™ II (B&D, USA).
Cell invasion assay. After reaching 80% confluence, the SCC-6 cells (1x10 5 ) were trypsinized and resuspended in the inner chamber of the insert in 200 µl of serum-free DMEM/F12 medium. DMEM/F12 medium (500 µl)with or without 10% FBS was added to the lower chamber. Between two chambers was the matrigel gel (B&D) diluted by serum-free DMEM/ F12 medium and placed on the surface of filtration membrane of the Transwell micropore with an aperture of 8 µm. TSA at different concentrations (0, 50, 100, 200, 400, 800 nmol/l) was added to the inner chamber and equivalent dehydrated alcohol as a control. After incubated at 37˚C for 24 h, the medium non-invading cells and the extracellular matrigel gel were gently removed by a cotton-tipped swab, and the layer of invasive cells gently washed by PBS. The number of invasive cells that migrated through the gel insert to the lower surface of the membrane were stained and photographed. Results were presented as the mean percentage of the control (control OD at 562 nm assigned as 100%). Experiments were done in triplicate and repeated three times.
Real-time reverse transcription polymerase chain reaction (real-time PCR)
. SCC-6 cells were treated with varied concentrations of DFX or/and TSA at different time periods, respectively. Total RNA was prepared using TRIzol reagent (Invitrogen, USA), and cDNA was synthesized by PrimeScript ® RT reagent kit (Takara, China). HIF-1α and VEGF mRNA expression was evaluated quantitatively by real-time RT-PCR with SYBR ® Premix Ex Taq™ (Takara) and ABI PRISMR 7900HT real-time PCR system (35) . The thermocycler conditions were preheating at 95˚C for 30 sec, cycles of 95˚C for 5 sec, 60˚C for 30 sec. The relative amount of PCR product was evaluated as threshold cycle (CT value) of the sample divided by that of β-actin. All experiments were done in triplicate and repeated three times. The primers were synthesized (Sangon, China) and the sequences were: HIF-1α: forward 5'-GAA CCTGATGCTTTAAACT-3', reverse 5'-CAACTGATCGAA GGAACG-3'; VEGF: forward 5'-TTTCTGCTGTCTTGG GTGCATTGG-3', reverse 5'-TCTGCATGGTGATGTTGGA CTCCT-3'; β-actin: forward 5'-TGGCACCCAGCACAAT GAA-3', reverse 5'-CTAAGTCATAGTCCGCCTAGAA GCA-3'.
Western blot analysis. After SCC-6 cells were treated with varied concentrations of DFX or/and TSA at different time periods. Cells were washed with ice-cold PBS twice and treated with buffer (50 mmol/l Tris-HCl (pH 7.5), 5 mmol/l EDTA, 150 mmol/l NaCl, 0.5% Triton X-100, 10 mmol/l sodium fluoride, 20 mmol/l h-mercaptoethanol, 250 Amol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride 50 mmol/l Tris-HCl (pH 7.5), 5 mmol/l EDTA, 150 mmol/l NaCl, 0.5% Triton X-100, 10 mmol/l sodium fluoride, 20 mmol/l β-mercaptoethanol, 250 µmol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonyl fluoride). The lysates were centrifuged at 1000 rpm for 10 min and the supernatants were collected and stored at -80˚C. Protein concentrations were determined by bicinchoninic acid assay methods (BCA protein assay kit, Thermo, USA). Equivalent amount of protein (40 µg) were loaded into 8-12% SDS-PAGE gel and electroblotted onto protein nitrocellulose membrane (Sigma). The NC membrane was rinsed in PBS-T solution (0.1% Tween-20 in PBS, pH 7.5) and blocked with 5% skim milk in PBS-T at room temperature. The membrane was incubated with HIF-1α (1:200) and VEGF (1:500) antibody overnight at 4˚C and washed with PBS-T four times every 10 min, then incubated with secondary antibody against rabbit (HIF-1α) and mouse (VEGF) (1:2000) at room temperature for 1 h and washed with PBS-T four times every 10 min (36, 37) . The signals were visualized by enhanced chemiluminescence using Odyssey chemiluminescence system (LI-COR, USA).
Statistical analysis. Statistical analysis was performed using the SPSS 14.0 software package. Data were expressed as the means ± SD. A paired Student's test was used for statistical analysis, with significant differences determined as p<0.05. (Fig. 1) . These results suggest that TSA inhibited the proliferation of SCC-6 cells in a dose-and time-dependent manner. (Fig. 2) , indicating that TSA induced cell apoptosis of SCC-6 cells in a dose-and time-dependent manner, and this effect might be related to the cell cycle blockade at S and G 2 /M phase. (Fig. 3) . Thus, TSA blocked the cell cycle of SCC-6 cells at S and G 2 /M phase.
Results
TSA inhibited cell proliferation of SCC
Apoptosis of SCC-6 cells induced by
Effect
Cell invasion inhibited by TSA of SCC-6 cells.
A previous study had shown the possible function of HIF-1α in the regulation of colon carcinoma cell invasion (38) . To investigate TSA cancer cell invasion of SCC-6 cells in vitro, we applied the transwell assay. After SCC-6 cells were treated with indicated concentrations of TSA, incubated in the transwell chamber for 24 h, viola crystalline staining was used to discriminate the cells passing through the matrigel membrane which represent the invasive abilities of SCC-6 cells (Fig. 4A ). As shown (Fig. 4B) , with the concentrations of TSA increased, the number of SCC-6 cells passing through the matrigel membrane significantly decreased and the inhibition rate of cell invasion increased (12 
Expression of HIF-1α and VEGF induced by hypoxia.
Hypoxia, a common microenvironment in aggressive solid tumors regulating many transcriptional factors including HIF-1α, which controls hypoxia-inducible angiogenic factors such as VEGF (39) . As shown (Fig. 5A and C) , under normoxia, control or mimic hypoxia (DFX 150 nmol/l) groups, no significant change in HIF-1α mRNA transcript was observed (p>0.05, Fig. 5E ); basal level of VEGF mRNA expression was observed under normoxia and it became more obviously under mimic hypoxia (p<0.05, Fig. 5E ) which increased with time and was significantly expressed at 24 h (Fig. 5C ). Western blot assay demonstrated that hypoxia induced rapid and sustained HIF-1α and VEGF protein accumulation in SCC-6 cells in a time-dependent manner which was significant up to 24 h ( Fig. 5B and D) . These data prove the instability of HIF-1α under normoxic conditions and that it stabilizes under hypoxic conditions, which suggests the hypoxic regulation of HIF-1α is at the protein level. The expression of mRNA and protein levels of VEGF, a direct downstream gene of HIF-1α, increases significantly as the activity of HIF-1α increases.
TSA inhibited hypoxia-induced accumulation of HIF-1α protein
and VEGF expression under hypoxic conditions. As shown (Fig. 6A) , no apparent changes in HIF-1α mRNA were observed in SCC-6 cells after exposed to hypoxia and TSA (800 nmol/l) for 24 h, and different concentrations and time intervals of TSA also had no effect on HIF-1α mRNA expression by RT-PCR (Fig. 6C, E and G) . The results of western blotting showed a low but detectable and steady-state basal level of HIF-1α protein expression under normoxia and increasing significantly under hypoxia (Figs. 5B and 6B) . To investigate the temporal effects of TSA on baseline of HIF-1α protein expression, we treated SCC-6 cells with 800 nmol/l TSA under normoxic and found that basal level of HIF-1α protein expression was reduced to low or undetectable (Fig. 6B) . To explore whether TSA could also inhibit hypoxia-induced HIF-1α protein expression, SCC-6 cells were treated with different concentrations and time intervals of TSA under hypoxia, the results showed that TSA inhibited hypoxia-induced HIF-1α protein accumulation in a concentration and time-dependent manner ( Fig. 6D and F) . Markedly, this inhibitory effect was not due to a decrease in its mRNA level, suggesting that TSA inhibited hypoxia-induced HIF-1α protein accumulation through a post-transcriptional mechanism. VEGF, an immediate downstream target gene of HIF-1α, plays a pivotal role in tumor angiogenesis under conditions of intratumoral hypoxia (23, 40) . To explore whether TSA could inhibit hypoxia-induced VEGF expression, we examined VEGF expression by RT-PCR and western blotting. The results showed an obvious decrease of VEGF mRNA and protein level expression after SCC-6 cells were treated with TSA at both basal and hypoxia-induced level (Fig. 6A, B and G) . To further confirm the effects of TSA on VEGF expression, SCC-6 cells were treated with different concentrations and time intervals of TSA under hypoxia. Our results indicated that the robust increase in VEGF mRNA and protein level expression induced by hypoxia was significantly suppressed by TSA in a doseand time-dependent manner (Fig. 6C-F) . Together, these data suggested that TSA inhibited hypoxia-induced angiogenesis through concurrent suppression of HIF-1α and VEGF. The viability of SCC-6 cells showed no apparent changes in cell morphology or toxicity at the above concentrations of TSA for 12 h (Fig. 1) , indicating that this inhibitory effect by TSA was not ascribed to nonspecific tumor cell toxicity.
Discussion
Histone deacetylation and acetylation is considered as a key regulatory mechanism of gene transcription. Histone deacetylases (HDACs) act to oppose the activity of histone acetyltransferases (HATs). The dysfunction of HDACs and HATs may lead to tumorigenesis which has been confirmed in leukemia (41) . Past research demonstrated that HDAC inhibitor exerts anticancer activity via suppression of HDAC activity, induction of histone acetylation and regulation of gene transcription (42, 43) . Recently, specific HDAC inhibitors such as LAQ824, FK228, sodium butyrate, resveratrol and trichostatin A have been reported to inhibit tumor growth, survival, metastasis and downregulate HIF-1α stability in many cancer cell lines (44) (45) (46) (47) (48) . HIF-1α, regulated by hypoxia, trans actives many target genes encoding proteins related to tumor angiogenesis, regulation of blood vessel tone, and vascular remodelling by HIF-1α mediated overexpression of VEGF and NO; cell proliferation and viability by IGF-2; erythropoiesis and iron metabolism by EPO; glucose transport and glycolysis by GLU-1,3, which makes HIF-1α a key transcriptional factor in tumor cell survival (13) .
In this study, we adopted a potent HDAC inhibitor, trichostatin A (TSA), with anticancer activity. It was first reported to induce cell differentiation in mice leukemia cells by Yoashi in 1987 (49) , demonstrated to inhibit tumor cell proliferation, block cell cycle, induce cell apoptosis and differentiation, block tumor angiogenesis in vitro and in vivo, via upregulating p53 and VHL expression and downregulating HIF-1α and VEGF (12, 50) . TSA significantly inhibited cell proliferation of SCC-6 cells in vitro in a dose-and time-dependent manner ( Fig. 1) which was partially related to TSA-induced cell apoptosis with the same dose-and time-dependent manner (Fig. 2) . HIF-1α was the key regulator to cellular adaptation under hypoxia, at the same time, endoplasmic reticulum (ER) stress could be induced and resulted in inhibition of protein translation, which could induce the cells to enter the cell cycle, leading to mitogenic responses. Therefore, the proliferation of SCC-6 cells may be an integrated stress response involving an ER-generated signal and the cellular adaptation to hypoxia (51) . HIF-1α regulates target genes directly or indirectly relating to cell apoptosis, some of which play a dual role in regulating apoptosis of tumor cells, which makes HIF-1α both anti-apoptotic and pro-apoptotic. It is the oxygen tension that considered to determine whether HIF-1α function as antiapoptotic or pro-apoptotic. Blagosklonny et al reported that the stabilization of p53 protein depend on HIF-1α, resulting in the induction of apoptosis under hypoxia (52) . However, another study showed that HIF-1α might have a protective role in limiting hypoxia-induced apoptosis via suppression of caspase-3 activity (53) . There is a cell cycle specificity in some type of cell apoptosis, acting as different inducements in cell apoptosis at different cell cycle phases. Cell apoptosis occurs after cell cycle blockade at a certain phase (54, 55) . To investigate whether the TSA-induced cell apoptosis of SCC-6 cells is cell cycle specific, we analyzed cell cycles of SCC-6 cells after treated with TSA by FCM. The percentage of cells at G 2 /M phase increased and cells at G 0 /G 1 phase decreased as the concentration of TSA increased, which agreed with the change of cell apoptosis rate (Fig. 3) . Thus, we presume the TSA-induced cell apoptosis of SCC-6 cells is relevant to its cell cycle blockade at G 2 /M phase.
Cell invasion, involved in tumor metastasis and progression, is known to be upregulated by hypoxia, through hypoxiainduced expression of matrix metalloproteases (MMPs) and inhibition of E-cadherin and β-catenin. The present study analyzed the effect on cell invasion of SCC-6 cells by TSA applying a transwell assay in vitro. Results showed that after treated with different concentrations of TSA, cell numbers that passed through the extracellular matrices (ECM) reduced significantly and inversely correlated with the TSA concentrations (Fig. 4) . Thus, TSA inhibits cell invasion of SCC-6 cells in vitro in a dose-dependent manner.
HIF-1α is hydroxylated, acetylated and bound by the von Hipple-Lindau (pVHL) ubiquitin E3 ligase complex under normoxia, leading to HIF-1α polyubiquitination and proteosomal degradation. In contrast, under hypoxia, HIF-1α hydroxylation and acetylation are surppressed by low oxygen tension, leading to stabilization of HIF-1α, which translocates to the nucleus to bind HIF-1β and recruit CBP/p300 resulting in gene transcription. Hypoxia also induces HDACs expression which deacetylates HIF-1α to increase HIF-1α transcriptional activity. Thus, HDAC inhibitor reverses the activity of HDACs resulting in the degradation of HIF-1α (6, 28, 44, 46) . Our study demonstrated that TSA inhibited both basal level and hypoxiainduced HIF-1α protein accumulation and VEGF mRNA and protein expression under hypoxia (Figs. 5 and 6 ). This significant inhibitory effect of VEGF may play a direct and critical role in the inhibition of angiogenesis under hypoxic conditions. However, to investigate whether the anti-angiogenic activity of TSA is the hypoxia-specific regulated mechanism, an in vivo tumor generation experiments with SCC-6 cells is needed. Only when the results of in vivo experiments are in accordance with the outcome of the present in vitro experiments can we presume that the functional HIF-1α and its target, VEGF, play critical roles in tumor cells in the process of hypoxia-induced tumor angiogenesis.
In conclusion, our present study demonstrates that TSA, a HDAC inhibitor, function as a powerful anticancer agent in vitro through its potent inhibition of HIF-1α and its downstream target gene, VEGF, under hypoxia, a common characteristic of most solid cancers. We suggest that TSA can be further investigated as a novel anticancer agent targeting tumor angiogenesis via inhibition of HIF-1α activity and VEGF expression.
